Viewpoint Molecular Targeting Revenue and Competitors
Estimated Revenue & Valuation
- Viewpoint Molecular Targeting's estimated annual revenue is currently $3M per year.
- Viewpoint Molecular Targeting's estimated revenue per employee is $201,000
Employee Data
- Viewpoint Molecular Targeting has 15 Employees.
- Viewpoint Molecular Targeting grew their employee count by -56% last year.
Viewpoint Molecular Targeting's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Science Officer | Reveal Email/Phone |
2 | Chief Business Strategy Officer | Reveal Email/Phone |
3 | Business Manager | Reveal Email/Phone |
Viewpoint Molecular Targeting Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $28.4M | 57 | 33% | $75.8M | N/A |
#2 | $1.2M | 6 | -73% | N/A | N/A |
#3 | $26.3M | 131 | 3% | N/A | N/A |
#4 | $33.4M | 166 | 2% | N/A | N/A |
#5 | $1073.9M | 5343 | 8% | N/A | N/A |
#6 | $9M | 45 | 10% | N/A | N/A |
#7 | $20.5M | 102 | 52% | N/A | N/A |
#8 | $20.1M | 100 | 37% | N/A | N/A |
#9 | $9.2M | 46 | 10% | N/A | N/A |
#10 | $3M | 15 | -56% | N/A | N/A |
What Is Viewpoint Molecular Targeting?
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company's leading ð›¼-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic†approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-ð›¼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$3M
Revenue (est)
-56%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Coralville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 19 | -24% | N/A |
#2 | $1.7M | 19 | 6% | N/A |
#3 | $2.4M | 24 | -4% | N/A |
#4 | $6.5M | 26 | 24% | N/A |
#5 | $2.8M | 28 | -10% | N/A |